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ABSTRACT 
Introduction: Although being overweight or obese is a risk factor for cardiovascular disease, 
obese subjects often live longer than their lean peers, and this is known as the obesity paradox. 
We investigated the impact of obesity on cardiac prognosis in chronic heart failure (CHF) pa-
tients, with or without metabolic syndrome. 
Design and Methods: We divided 374 consecutive CHF patients into two groups according to 
their mean body mass index (BMI) and prospectively followed them for 2 years.  
Results: There were 126 cardiac events, including 32 cardiac deaths and 94 re-hospitalizations. 
Kaplan-Meier analysis revealed a significantly lower cardiac event rate in the higher BMI 
group (log-rank test P < 0.001) in all patients and those patients without metabolic syndrome. 
There was no association between BMI and cardiac prognosis in patients with metabolic syn-
drome. Cox hazard analysis revealed that a higher BMI was associated with favorable cardiac 
outcomes in all patients and patients without metabolic syndrome, after adjusting for con-
founding factors. However, this finding did not extend to patients with metabolic syndrome. 
Conclusions: The advantages of obesity are not found in CHF patients with metabolic syn-
drome. 
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INTRODUCTION 
The increasing number of overweight or 
obese individuals in developed countries is 
linked to excessive calorie intake and re-
duced physical activity. Importantly, being 
overweight or obese is associated with the 
development of cardiovascular diseases, type 
II diabetes mellitus, stroke, respiratory prob-
lems, and psychological disorders (Dagenais 
et al., 2005; Wilson et al., 2002). Several co-
hort studies showed that a high body mass 
index (BMI) is associated with an increased 
risk for coronary artery disease, heart failure, 
and cardiac death (Calle et al., 1999; 
Dagenais et al., 2005). However, a number 
of studies reported that obese subjects often 
live longer than their lean peers, and this is 
termed the obesity paradox (Gastelurrutia et 
al., 2011; Horwich et al., 2001). Previously, 
obese patients with chronic heart failure 
(CHF) were found to have better prognoses 
compared with lean patients (Komukai et al., 
2012). In contrast, the prevalence of cardiac 
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cachexia increases with advancing CHF and 
is associated with poor prognosis (Anker and 
Sharma, 2002). However, it remains unclear 
whether obesity influences favorable out-
comes in patients with CHF. 
Increased abdominal visceral adipose tis-
sues are able to produce adipocytokines, 
which induce chronic systemic inflammation 
(Libby et al., 2002). Chronic inflammation 
of visceral adipose tissue in turns raises insu-
lin resistance, which is associated with sym-
pathetic nerve activation and renin –an-
giotensin -aldosterone system activation in 
obese subjects (Patel and Abate, 2013; 
Shimizu et al., 2012). Therefore, we hypo-
thesized that the presence of insulin re-
sistance would negate any advantage of obe-
sity in patients with CHF. 
In the present study, we investigated the 
effect of obesity on cardiac prognosis in 
CHF patients with or without metabolic syn-
drome. 
 
PATIENTS AND METHODS 
Study population 
Between September 2009 and October 
2011, 469 consecutive patients were admit-
ted to the Yamagata University Hospital for 
treatment of worsening CHF, for diagnosis 
and pathophysiological investigations, or for 
therapeutic evaluation of CHF. The diagno-
sis of CHF was based on a history of dysp-
nea and symptoms of exercise intolerance 
followed by pulmonary congestion, pleural 
effusion, or left ventricular enlargement by 
chest X-ray or echocardiography (Jessup et 
al., 2009; McKee et al., 1971). Five patients 
undergoing chronic hemodialysis and 14 pa-
tients with no weight or height information 
in their medical records were excluded. For-
ty-nine patients with no recorded serum al-
bumin level were also excluded. The remain-
ing 401 patients were prospectively followed 
(Figure 1). Informed consent was obtained 
from all patients before participation, and the 
protocol was approved by the institution’s 
Human Investigation Committee. The proce-
dures were performed in accordance with the 
Helsinki Declaration. 
 
Definition of metabolic syndrome 
We defined metabolic syndrome accor-
ding to the National Cholesterol Education 
program Adult Treatment Panel III (NCEP-
ATP III) criteria (Expert Panel on Detection, 
Evaluation, and Treatment of High Blood 
Cholesterol in Adults, 2001). We modified 
the NCEP-ATP III criteria for abdominal 
obesity by using a BMI ≥ 25 kg/m2 instead of 
waist circumference (Hao et al., 2007). Met-
abolic syndrome requires at least three of the 
following five criteria:  
 BMI ≥ 25 kg/m2,  
 elevated triglyceride ≥ 150 mg/dL,  
 reduced high-density lipoprotein choles-
terol < 40 mg/dL in men and < 50 mg/dL 
in women,  
 elevated fasting blood sugar ≥ 110 mg/dL 
or previously diagnosed diabetes mellitus,  
 elevated blood pressure (systolic blood 
pressure ≥  130 mmHg, and/or diastolic 
blood pressure ≥ 85 mmHg), or antihyper-
tensive medication use. 
 
End points and follow-up 
The patients were prospectively followed 
for 2 years. The end points were cardiac 
death, including death due to progressive 
CHF, myocardial infarction, stroke, other 
vascular causes, and sudden cardiac death, or 
re-hospitalization for worsening CHF. Sud-
den cardiac death was defined as death with-
out definite premonitory symptoms or signs, 
and was confirmed by the attending physi-
cian. Two cardiologists, who were blinded to 
the blood biomarker data, reviewed the med-
ical records and conducted telephone inter-
views to survey the incidence of cardiovas-
cular events.  
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Figure 1: Recruitment of patients with chronic heart failure 
 
 
Statistical analysis 
Continuous data are expressed as means 
± standard deviation (SD), and skewed data 
are presented as medians with interquartile 
range. The unpaired Student’s t-test and chi-
square test were used to compare con-
tinuous and categorical variables, respective-
ly. The Mann-Whitney U-test was employed 
when the data were not normally distributed. 
A comparison of serum brain natriuretic pep-
tide (BNP) levels and BMI tertiles was per-
formed with Pearson’s chi-square tests. Uni- 
and multivariate analyses with Cox propor-
tional hazard regression were used to deter-
mine significant predictors of cardiovascular 
events. Multivariate analysis was adjusted by 
factors that were found to be significant in 
univariate analysis. Cumulative overall and 
event-free survival rates were computed us-
ing the Kaplan-Meier method and were 
compared using the log-rank test. A P value 
< 0.05 was considered statistically signifi-
cant. All statistical analyses were performed 
with a standard statistical program package 
(JMP version 10; SAS Institute, Cary, North 
Carolina). 
 
RESULTS 
Patient characteristics 
Twelve patients who underwent cardiac 
surgery during the follow-up period were ex-
cluded from analysis, and 15 patients were 
lost to follow-up. The remaining 374 patients 
were included in final analysis (Figure 1). 
Patient baseline characteristics are listed in 
Table 1. There were 223 males (60 %), and 
the mean age was 68 ± 12 years. There were 
151 patients in New York Heart Association 
(NYHA) functional class III and IV. Heart 
failure etiology was identified as dilated car-
diomyopathy in 102 (27 %) patients, valvu-
lar heart disease in 84 (23 %) patients, is-
chemic heart disease in 59 (16 %) patients, 
hypertensive heart disease in 44 (12 %) pa-
tients, hypertrophic cardiomyopathy in 19 
(5 %) patients, and others in the remaining 
66 (17 %) patients. Mean left ventricular 
ejection fraction as measured by echocardi-
ography was 50 ± 17 %, and the median se-
rum BNP level was 362 ng/L (interquartile 
range: 141.8-874.0).  
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Comparison between patients with and 
without metabolic syndrome 
There were 52 patients (14 %) with met-
abolic syndrome. They were younger and 
had higher BMIs compared with those with-
out metabolic syndrome (Table 1). There 
were no significant differences in etiologies 
of CHF or medications. 
Comparison between patients with and 
without cardiac events 
There were 126 cardiac events (34 %), 
including 32 cardiac deaths and 94 re-
hospitalizations, during the follow-up period 
(Table 2). The patients who experienced 
 
Table 1: Baseline clinical characteristics and clinical characteristics of CHF patients with and without 
metabolic syndrome 
 All Patients  (n=374) 
Non-MetS 
(n=322) 
MetS 
(n=52) P value 
Age (years) 68 ± 12 70 ± 12 66 ± 13 0.011 
Male, n (%) 223 (60) 189 (59) 34 (65) 0.361 
NYHA functional class, II/III/IV 223/98/55 187/84/51 36/13/3 0.186 
Etiology, n (%)     
Dilated cardiomyopathy 102 (27) 89 (28) 13 (25) 0.691 
Valvular heart disease 84 (23) 76 (24) 8 (15) 0.187 
Ischemic heart disease 59 (16) 49 (15) 10 (19) 0.461 
Hypertensive heart disease 44 (12) 35 (11) 9 (17) 0.181 
Hypertrophic cardiomyopathy 19 (5) 15 (5) 4 (8) 0.355 
Others 66 (17) 58 (17) 11 (16) 0.784 
Presentation profile     
Systolic pressure, mmHg 133 ± 15 135 ± 16 134 ± 15 0.659 
Diastolic pressure, mmHg 78 ± 9 76 ± 10 75 ± 10 0.522 
Body mass index, kg/m2 22.2 ± 3.6 21.8 ± 3.3 25.1 ± 3.8 < 0.001 
eGFR, ml/min/1.73m2 62 ± 27 62 ± 25 62 ± 25 0.942 
Blood biomarkers     
Total protein, g/dl  6.5 ± 0.7 6.5 ± 0.7 6.6 ± 0.5 0.095 
Albumin, g/dl  3.6 ± 1.9 3.6 ± 2.0 3.7 ± 0.6 0.756 
Total cholesterol, mg/dl 173 ± 41 135 ± 16 160 ± 76 0.869 
Triglyceride, mg/dl 98 ± 57 92 ± 50 139 ± 50 < 0.001 
LDLc, mg/dl 99 ± 32 98 ± 30 108 ± 39 0.039 
HDLc, mg/dl 53 ± 20 50 ± 17 43 ± 14 < 0.001 
BNP, pg/ml (IQR) 362 (142-874) 377 (152-905) 197 (72-848) 0.273 
Echocardiographic data     
LV end-diastolic diameter, mm 55 ± 10 55 ± 10 57 ± 9 0.108 
LV ejection fraction, % 50 ± 17 50 ± 17 51 ± 18 0.883 
Medications, n (%)     
ACE inhibitors and/or ARBs 263 (70) 228 (71) 35 (67) 0.608 
β blockers 188 (50) 166 (52) 22 (42) 0.216 
Ca channel blockers 84 (23) 70 (22) 14 (27) 0.405 
Statins 90 (24) 77 (24) 13 (25) 0.864 
Data are presented as mean ± SD or % unless otherwise indicated; IQR, interquartile range; ACE, angiotensin-converting en-
zyme; ARB, angiotensin receptor blocker; BNP, brain natriuretic peptide; eGFR, estimated glomerular filtration rate; HDLc, high 
density lipoprotein cholesterol; LDLc, low density lipoprotein cholesterol; LV, left ventricular; MetS, metabolic syndrome; NYHA, 
New York Heart Association  
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Table 2: Clinical characteristics of CHF patients with and without cardiac events 
 Event (-) (n=248) 
Event (+) 
(n=126) P value 
Age (years) 68 ± 12 72 ± 11 0.007 
Male, n (%) 141 (57) 34 (61) 0.125 
NYHA functional class, II/III/IV 166/52/30 57/45/24 <0.001 
Etiology, n (%)    
Dilated cardiomyopathy 61 (25) 41 (33) 0.103 
Valvular heart disease 61 (25) 23 (18) 0.164 
Ischemic heart disease 35 (14) 24 (19) 0.215 
Hypertensive heart disease  33 (13) 11 (9) 0.194 
Hypertrophic cardiomyopathy 14 (6) 5 (4) 0.485 
Others 44 (17) 22 (17) 0.899 
Presentation profile    
Systolic pressure, mmHg 134 ± 15 134 ± 16 0.621 
Diastolic pressure, mmHg 79 ± 10 79 ± 9 0.428 
Body mass index, kg/m2 22.6 ± 3.6 21.5 ± 3.4 0.002 
eGFR, ml/min/1.73m2 63 ± 29 60 ± 21 0.294 
Blood biomarkers    
Total protein, g/dl  6.6 ± 0.7 6.4 ± 0.8 0.019 
Albumin, g/dl  3.9 ± 2.2 3.1 ± 0.8 <0.001 
Total cholesterol, mg/dl 178 ± 39 165 ± 46 0.008 
Triglyceride, mg/dl  104 ± 62 87 ± 44 0.008 
LDLc, mg/dl 101 ± 32 96 ± 32 0.192 
HDLc, mg/dl 54 ± 22 50 ± 16 0.037 
BNP, pg/ml (IQR) 583 (123-661) 853 (220-1230) 0.041 
Echocardiographic data    
LV end-diastolic diameter, mm 55 ± 10 56 ± 10 0.102 
LV ejection fraction, % 52 ± 17 47 ± 17 0.003 
Medications, n (%)    
ACE inhibitors and/or ARBs 169 (68) 94 (75) 0.196 
β blockers 116 (47) 72 (57) 0.058 
Ca channel blockers 50 (20) 34 (27) 0.059 
Statins 52 (21) 38 (31) 0.135 
Data are presented as mean ± SD or % unless otherwise indicated; IQR, interquartile range; ACE, 
angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BNP, brain natriuretic peptide; 
eGFR, estimated glomerular filtration rate; HDLc, high density lipoprotein cholesterol; LDLc, low 
density lipoprotein cholesterol; LV, left ventricular; NYHA, New York Heart Association 
	
 
cardiac events were older, in a more severe 
NYHA functional class, and showed lower 
BMI and left ventricular ejection fraction 
compared with those who did not. Moreover, 
patients with cardiac events showed lower 
serum levels of total protein, albumin, total 
cholesterol, triglyceride, high-density lipo-
protein cholesterol, and higher serum BNP 
levels compared with those who did not ex-
perience events. There were no significant 
differences in etiologies of CHF or medica-
tions between patients with and without car-
diac events. 
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Association between BMI and serum BNP 
levels 
The patients were divided into two 
groups according to their mean BMI (lower 
G1 and higher G2), respectively. In all CHF 
patients, and those without metabolic syn-
drome, serum BNP levels were higher in 
lower serum BMI groups than in higher se-
rum BMI groups (both P < 0.001; Figure 2A, 
B). However, there was no association be-
tween BMI and serum BNP levels in patients 
with metabolic syndrome (P = 0.207, Figure 
2C).  
 
Association between BMI and cardiac 
events 
In univariate Cox hazard analysis, the 
unadjusted hazard ratio (HR) for cardiac 
events was significantly decreased with in-
creasing BMI in all patients (G2: unadjusted 
HR 0.48, 95 % confidence interval (CI) 0.33-
0.69) and patients without metabolic syn-
drome (G2: unadjusted HR 0.45, 95 % CI 
0.30-0.67) but not in those with metabolic 
syndrome (G2: unadjusted HR 1.81, 95 % CI 
0.70-4.62) (Table 3). Multivariate analysis 
revealed that a higher BMI was associated 
with the lower risk in all patients and those 
without metabolic syndrome after adjust-
ments for age, gender, NYHA functional 
class, and serum BNP levels (adjusted HR 
0.55, 95 % CI 0.38-0.79; adjusted HR 0.52, 
95 % CI 0.35-0.79; respectively). Kaplan-
Meier analysis revealed that significantly 
lower cardiac event rates were observed in 
higher BMI (G2) in both CHF patients and 
patients without metabolic syndrome (log-
rank test, both P < 0.001; Figure 3A, B). 
Meanwhile, there was no significant associa-
tion between BMI and cardiac events in pa-
tients with metabolic syndrome (log-rank 
test P = 0.220, Figure 3C). 
 
DISCUSSION 
The present study has demonstrated that 
obese patients with CHF had a better cardiac 
prognosis than lean patients, consistent with 
previous reports (Horwich et al., 2001; 
Komukai et al., 2012). However, favorable 
cardiac outcomes were not observed in obese 
patients with metabolic syndrome. 
Although being overweight or obese is a 
well-recognized independent risk factor for 
cardiovascular diseases, a large number of 
cohort studies have shown that obesity is not 
necessarily associated with increased mortal-
ity in patients with CHF, but can be associat-
ed with a favorable prognosis in patients 
with CHF (Gastelurrutia et al., 2011; 
Kenchaiah et al., 2007). The present study 
also demonstrated that obese patients with
 
Table 3: Unadjusted and adjusted hazard ratio for factors predicting cardiovascular events in heart 
failure patients with and without metabolic syndrome 
 Unadjusted HR 95 % CI P value 
Adjusted 
HR 95 % CI P value 
All patients       
G1 1 Reference Reference    
G2 0.48 0.33-0.69 <0.001 0.55 0.38-0.79 0.001 
Non-MetS patients       
G1 1 Reference Reference    
G2 0.45 0.31-0.67 <0.001 0.52 0.35-0.79 0.002 
MetS patients       
G1 1 Reference Reference    
G2 1.81 0.70-4.62 0.219 - - - 
CI, confidence interval; HR, hazard ratio; MetS, metabolic syndrome. Adjusted HR, after adjustment of age, gender, New 
York Heart Association functional class, and serum levels of brain natriuretic peptide 
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Figure 2: The association between BMI and serum BNP level. A: In all CHF patients, serum BNP lev-
els decreased with increasing BMI (P < 0.001). B: In patients without metabolic syndrome, serum BNP 
levels also decreased with increasing BMI (P < 0.001). C: There was no association between BMI and 
serum BNP levels in patients with metabolic syndrome (P = 0.207). (BMI, body mass index; BNP, 
brain natriuretic peptide; CHF, chronic heart failure) 
 
	
Figure 3: Kaplan-Meier analysis A: Significantly lower cardiac event rates were observed in higher 
BMI (G2) in all CHF patients (log-rank test, P < 0.001). B: Significantly lower cardiac event rates were 
also observed in higher BMI (G2) in CHF patients without metabolic syndrome (log-rank test, P < 
0.001). C: A survival rate did not have significant difference between two groups (log-rank test, P = 
0.220). (BMI, body mass index; CHF, chronic heart failure) 
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CHF have a better cardiac prognosis than 
lean patients. However, the pathophysiologi-
cal mechanism of the obesity paradox re-
mains unclear. Curtis et al. hypothesized that 
because cardiac output and myocardial de-
mands are increased in obese patients, heart 
failure may be diagnosed earlier than in lean 
patients (Curtis et al., 2005). Komukai et al. 
(2012) also hypothesized that CHF is a cata-
bolic state and because obese patients have 
greater metabolic reserve, obese patients 
may have better prognoses. Kistorp et al. 
(2005) reported that high levels of adiponec-
tin, which is a well-known adipocyte-
specific cytokine that is decreased in obesity, 
are associated with an increased risk of mor-
tality in patients with CHF.  
However the prevalence of cardiac ca-
chexia is increased with worsening CHF, 
which is associated with a poor prognosis in 
patients with advanced CHF (Anker and 
Sharma, 2002). Anker et al. (1997) reported 
that the prevalence of cardiac cachexia was 
42 % in CHF outpatients, and patients with 
cardiac cachexia showed 50 % mortality at 
18 -months, which is comparable or higher 
than that in patients with malignant tumors. 
It was reported that several inflammatory cy-
tokines, such as interleukin 1, interleukin 6, 
and tumor necrosis factor alpha, are elevated 
in patients with CHF, and induce chronic in-
flammation and metabolic disorder due to in-
sulin resistance (Berry and Clark, 2000; 
Levine et al., 1990). These immune and neu-
rohormonal abnormalities may contribute to 
the development of cardiac cachexia and a 
poorer cardiac prognosis. 
Several studies reported that obese pa-
tients with additional risk factors (e.g., meta-
bolic syndrome) are at a substantially higher 
risk of developing cardiovascular disease 
(Echahidi et al., 2007; Kajimoto et al., 2009). 
Nakamura et al. (2001) found that patients 
with metabolic syndrome were at a 31.3–fold 
greater risk of cardiovascular disease com-
pared to those without. Shimizu et al. (2012) 
reported that chronic pressure overload in 
patients with CHF raises insulin resistance, 
which leads to metabolic syndrome. Individ-
uals with metabolic syndrome produce vari-
ous cytokines and develop a catabolic state 
due to chronic adipose tissue inflammation 
and insulin resistance (Ashrafian et al., 2007). 
Because insulin resistance is associated with 
sympathetic nerve activation and renin –
angiotensin -aldosterone system activation 
(Shimizu et al., 2012), favorable cardiac out-
comes are not observed in obese patients 
with metabolic syndrome. The presence of 
insulin resistance may negate the advantages 
previously described in obese patients with 
CHF. However, further investigation is re-
quired to elucidate the mechanism by which 
metabolic syndrome results in a poorer car-
diac prognosis in obese patients with CHF. 
There were several limitations in the pre-
sent study. First, the number of CHF patients 
with metabolic syndrome was small in the 
present study. The prevalence of metabolic 
syndrome was reported to be 7-20 % in the 
general population and 20-40 % in patients 
with CHF in Japan (Hao et al., 2007; Miura 
et al., 2010). Our results corresponded with 
these reports. Although statistical analysis 
was possible for CHF patients with metabol-
ic syndrome, future study will need to clarify 
the association between obesity paradox and 
CHF patients with metabolic syndrome in 
large population. Second, because data re-
garding waist circumference were not avail-
able, we modified the NCEP-ATP III criteria 
for abdominal obesity and used a BMI ≥ 25 
kg/m2 (Hao et al., 2007). Third, the BMI dis-
tribution of our study patients was lower 
than that reported in studies carried out in 
European countries and in the United States 
(Gastelurrutia et al., 2011). Therefore, we 
defined obesity as a BMI ≥ 25 kg/m2 by us-
ing Japanese criteria (Examination Com-
mittee of Criteria for 'Obesity Disease' in 
Japan, 2002). 
In conclusion, favorable cardiac out-
comes were observed in obese CHF patients 
without metabolic syndrome. However, there 
was no favorable impact of obesity on clini-
cal outcomes in CHF patients with metabolic 
syndrome.  
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